LEADER 04190nam 22007215 450 001 9910255190803321 005 20230810230450.0 010 $a3-662-49655-0 024 7 $a10.1007/978-3-662-49655-8 035 $a(CKB)3710000000765573 035 $a(DE-He213)978-3-662-49655-8 035 $a(MiAaPQ)EBC4612519 035 $a(PPN)228317487 035 $a(EXLCZ)993710000000765573 100 $a20160725d2016 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAccess to Medicine Versus Test Data Exclusivity $eSafeguarding Flexibilities Under International Law /$fby Owais H. Shaikh 205 $a1st ed. 2016. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2016. 215 $a1 online resource (XVI, 256 p. 78 illus., 56 illus. in color.) 225 1 $aMunich Studies on Innovation and Competition,$x2199-7470 ;$v4 311 $a3-662-49654-2 320 $aIncludes bibliographical references. 327 $aIntroduction -- Test Data Exclusivity: Raison d'être -- Test Data Exclusivity and Art 39(3) TRIPS -- Test Data Exclusivity in the US and the EU -- Index of Data Exclusivity and Access (IDEAS) - Free Trade Agreements -- Index of Data Exclusivity and Access (IDEAS) - National Laws -- Test Data Exclusivity in FTAs and Access to Originator Pharmaceuticals -- Conclusions and Recommendations. 330 $aThis book explores the concept of test data exclusivity protection for pharmaceuticals. Focusing on Art 39(3) of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) and relevant provisions in selected free trade agreements (FTA) and national laws, it combines normative, historical, comparative and economic analysis of test data exclusivity protection. At the heart of this book is the novel and original Index of Data Exclusivity and Access (IDEAS), which analyzes the effectiveness of test data exclusivity provisions in FTAs and national laws both on the strength of exclusivity as well as on access to medicine. IDEAS provides a framework for the assessment of current test data exclusivity protection standards on the basis of their proximity to Article 39(3) of the TRIPS Agreement, the scope of exclusivity and the flexibilities in FTAs, and subsequently in national laws. This book aims to broaden national and international policy makers? grasp of the various nuances of test data exclusivity protection. Furthermore, it provides practical recommendations with regard to designing an appropriate legal system with a strong focus on promoting access to medicine for all. 410 0$aMunich Studies on Innovation and Competition,$x2199-7470 ;$v4 606 $aInformation technology$xLaw and legislation 606 $aMass media$xLaw and legislation 606 $aConflict of laws 606 $aConflict of laws 606 $aInternational law 606 $aComparative law 606 $aTrade regulation 606 $aLaw and economics 606 $aIT Law, Media Law, Intellectual Property 606 $aPrivate International Law, International and Foreign Law, Comparative Law 606 $aInternational Economic Law, Trade Law 606 $aLaw and Economics 615 0$aInformation technology$xLaw and legislation. 615 0$aMass media$xLaw and legislation. 615 0$aConflict of laws. 615 0$aConflict of laws. 615 0$aInternational law. 615 0$aComparative law. 615 0$aTrade regulation. 615 0$aLaw and economics. 615 14$aIT Law, Media Law, Intellectual Property. 615 24$aPrivate International Law, International and Foreign Law, Comparative Law. 615 24$aInternational Economic Law, Trade Law. 615 24$aLaw and Economics. 676 $a340.9 700 $aShaikh$b Owais H$4aut$4http://id.loc.gov/vocabulary/relators/aut$01062331 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910255190803321 996 $aAccess to Medicine Versus Test Data Exclusivity$92524419 997 $aUNINA